Protagenic Therapeutics, Inc.\new — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Protagenic Therapeutics, Inc.\new filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $0 | Mar 31, 2025 |
| FY2024 | Dec 31, 2023 | $0 | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $0 | May 14, 2024 |
| FY2022 | Dec 31, 2021 | $0 | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $0 | Apr 7, 2022 |
| FY2016 | Dec 31, 2016 | $0 | May 8, 2017 |
| FY2016 | Dec 31, 2015 | $0 | May 8, 2017 |
| FY2014 | Jun 30, 2014 | $0 | Oct 14, 2014 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($5.53M) | Mar 31, 2025 |
| FY2024 | Dec 31, 2023 | ($5.00M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($3.56M) | May 14, 2024 |
| FY2022 | Dec 31, 2021 | ($4.52M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($2.55M) | Apr 7, 2022 |
| FY2020 | Dec 31, 2019 | ($1.75M) | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | ($2.56M) | Apr 29, 2020 |
| FY2018 | Dec 31, 2017 | ($2.26M) | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | ($2.28M) | Apr 2, 2018 |
| FY2016 | Dec 31, 2015 | ($1.02M) | May 8, 2017 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($5.70M) | Mar 31, 2025 |
| FY2024 | Dec 31, 2023 | ($4.53M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($3.56M) | May 14, 2024 |
| FY2022 | Dec 31, 2021 | ($4.14M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($2.55M) | Apr 7, 2022 |
| FY2020 | Dec 31, 2019 | ($2.09M) | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | ($2.31M) | Apr 29, 2020 |
| FY2018 | Dec 31, 2017 | ($2.37M) | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | ($2.23M) | Apr 2, 2018 |
| FY2016 | Dec 31, 2015 | ($1.03M) | May 8, 2017 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $3.84M | Mar 31, 2025 |
| FY2024 | Dec 31, 2023 | $3.06M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $1.59M | May 14, 2024 |
| FY2022 | Dec 31, 2021 | $1.14M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $699.8K | Apr 7, 2022 |
| FY2020 | Dec 31, 2019 | $807.9K | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | $881.2K | Apr 29, 2020 |
| FY2018 | Dec 31, 2017 | $717.5K | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | $417.9K | Apr 2, 2018 |
| FY2016 | Dec 31, 2015 | $456.3K | May 8, 2017 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($4.22M) | Mar 31, 2025 |
| FY2024 | Dec 31, 2023 | ($3.70M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($1.99M) | May 14, 2024 |
| FY2022 | Dec 31, 2021 | ($2.80M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($1.35M) | Apr 7, 2022 |
| FY2020 | Dec 31, 2019 | ($488.0K) | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | ($1.07M) | Apr 29, 2020 |
| FY2018 | Dec 31, 2017 | ($1.38M) | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | ($1.14M) | Apr 2, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2016 | Dec 31, 2015 | $1.8K | May 8, 2017 |
| FY2015 | Jun 30, 2015 | $1.0K | Sep 25, 2015 |
| FY2015 | Jun 30, 2014 | $1.0K | Sep 25, 2015 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $1.96M | Mar 31, 2025 |
| FY2024 | Dec 31, 2023 | $4.32M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $8.04M | May 14, 2024 |
| FY2022 | Dec 31, 2021 | $11.06M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $879.2K | Apr 7, 2022 |
| FY2020 | Dec 31, 2019 | $842.3K | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | $696.9K | Apr 29, 2020 |
| FY2018 | Dec 31, 2017 | $1.78M | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | $3.16M | Apr 2, 2018 |
| FY2016 | Dec 31, 2015 | $11.1K | May 8, 2017 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $942.8K | Mar 31, 2025 |
| FY2024 | Dec 31, 2023 | $655.3K | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $1.12M | May 14, 2024 |
| FY2022 | Dec 31, 2021 | $1.12M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $2.03M | Apr 7, 2022 |
| FY2020 | Dec 31, 2019 | $1.48M | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | $907.8K | Apr 29, 2020 |
| FY2015 | Jun 30, 2015 | $704.0K | Sep 25, 2015 |
| FY2015 | Jun 30, 2014 | $316.0K | Sep 25, 2015 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $1.01M | Mar 31, 2025 |
| FY2024 | Dec 31, 2023 | $3.67M | Mar 31, 2025 |
| FY2024 | Dec 31, 2022 | $6.92M | Mar 31, 2025 |
| FY2023 | Dec 31, 2021 | $9.94M | May 14, 2024 |
| FY2022 | Dec 31, 2020 | ($1.15M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2019 | ($634.4K) | Apr 7, 2022 |
| FY2020 | Dec 31, 2018 | ($210.9K) | Mar 25, 2021 |
| FY2019 | Dec 31, 2017 | $1.22M | Apr 29, 2020 |
| FY2018 | Dec 31, 2016 | $2.48M | Mar 29, 2019 |
| FY2017 | Dec 31, 2015 | ($667.2K) | Apr 2, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($36.30M) | Mar 31, 2025 |
| FY2024 | Dec 31, 2023 | ($30.78M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($25.78M) | May 14, 2024 |
| FY2022 | Dec 31, 2021 | ($22.22M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($17.70M) | Apr 7, 2022 |
| FY2020 | Dec 31, 2019 | ($15.15M) | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | ($13.40M) | Apr 29, 2020 |
| FY2018 | Dec 31, 2017 | ($10.84M) | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | ($8.58M) | Apr 2, 2018 |
| FY2016 | Dec 31, 2015 | ($6.31M) | May 8, 2017 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Dec 31, 2020 | $671.1K | Mar 25, 2021 |
| FY2020 | Dec 31, 2019 | $798.6K | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | $362.5K | Apr 29, 2020 |
| FY2018 | Dec 31, 2017 | $399.7K | Mar 29, 2019 |
| FY2018 | Dec 31, 2016 | $3.10M | Mar 29, 2019 |
| FY2017 | Dec 31, 2015 | $3.3K | Apr 2, 2018 |
| FY2015 | Jun 30, 2015 | $62.0K | Sep 25, 2015 |
| FY2016 | Dec 31, 2014 | $22.7K | May 8, 2017 |
| FY2015 | Jun 30, 2014 | $101.0K | Sep 25, 2015 |
| FY2015 | Jul 11, 2013 | $717.0K | Sep 25, 2015 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | (1) | Mar 31, 2025 |
| FY2024 | Dec 31, 2023 | (1) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | 0 | May 14, 2024 |
| FY2022 | Dec 31, 2021 | (1) | Mar 31, 2023 |
| FY2014 | Jun 30, 2014 | 0 | Oct 14, 2014 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | (1) | Mar 31, 2025 |
| FY2024 | Dec 31, 2023 | (1) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | 0 | May 14, 2024 |
| FY2014 | Jun 30, 2014 | 0 | Oct 14, 2014 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | 7.24M | Mar 31, 2025 |
| FY2024 | Dec 31, 2023 | 4.44M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | 4.32M | May 14, 2024 |
| FY2022 | Dec 31, 2021 | 4.30M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | 10.36M | Apr 7, 2022 |
| FY2020 | Dec 31, 2019 | 10.26M | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | 10.26M | Apr 29, 2020 |
| FY2018 | Dec 31, 2017 | 10.26M | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | 10.26M | Apr 2, 2018 |
| FY2016 | Dec 31, 2015 | 6.61M | May 8, 2017 |